Along with PD-L1 expression, other markers such as microsatellite instability and tumor mutation burden, as well as understanding the role of other markers and the function of tumor infiltrating immune and stromal cells in the tumor microenvironment may be important in predicting clinical benefit of immune checkpoint inhibition and determining optimal combination therapies.5, 6, 7, 8, 9, 10. Here, CD274 is linked to neoplasm.